Shelda Syifa’ Azzahra
General Practitioner, Udayana Level II Military Hospital, Indonesia / Graduate of Faculty of Medicine, Syiah Kuala University, Indonesia

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

COMPREHENSIVE SYSTEMATIC REVIEW OF THE ROLE OF ARTIFICIAL INTELLIGENCE-BASED COMPUTER-AIDED DETECTION ENDOSCOPY IN COLON POLYPS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES Muhammad Thoriq Alhabib; Namira Assyfa Nurazizah; Fikri Arif Muhammad; Chaerunnisa Auliya Putu Sugiyarti; Greatavia Meanda Leslie; Srigita Varsha; Dwi Putri Wijayanti; Fitri Nurina Septiana; Bernita Nur Cahyani; Shelda Syifa’ Azzahra; Muhamad Luthfi Asyhar; Charles Sanjaya
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/kcmyh598

Abstract

Background and aims: Adenoma detection rate (ADR) is the principal quality indicator of colonoscopy and is inversely associated with post-colonoscopy colorectal cancer (PCCRC). Artificial intelligence (AI)-based computer-aided detection (CADe) systems built on deep convolutional neural networks provide real-time visual alerts for suspected polyps. We aimed to comprehensively synthesise randomised and primary non-randomised evidence published in the last 15 years on the efficacy, effectiveness and diagnostic performance of CADe-assisted colonoscopy for colorectal polyp detection. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs were randomised controlled trials (RCTs), comparative studies, cohorts and case series; systematic reviews and meta-analyses were excluded from the evidence base and considered only in the discussion. Risk of bias was assessed with RoB 2, ROBINS-I and the JBI case-series checklist. Random-effects meta-analyses used restricted maximum-likelihood heterogeneity estimation with Hartung–Knapp–Sidik–Jonkman (HKSJ) confidence intervals and 95% prediction intervals (PI). Certainty of evidence was rated with GRADE. Results: Sixty-three studies were included (43 RCTs, 12 non-randomised comparative studies and 8 case/validation series; more than 79,000 colonoscopies). In 34 parallel-group RCTs (n = 34,010), CADe increased ADR from 41.4% to 47.4% (risk ratio [RR] 1.16 (95% CI 1.11–1.22); I² = 66%; 95% PI 0.94–1.43; low certainty). CADe halved the adenoma miss rate in tandem RCTs (RR 0.49 (95% CI 0.32–0.75); moderate certainty), increased polyp detection (RR 1.21 (95% CI 1.08–1.35)) and adenomas per colonoscopy (mean difference 0.27 (95% CI 0.15–0.38)), but did not increase detection of advanced adenoma/advanced neoplasia (RR 1.04 (95% CI 0.95–1.14)) or, with statistical certainty, serrated lesions (RR 1.48 (95% CI 0.80–2.73)). The relative benefit declined with higher control-arm ADR (meta-regression P < 0.001; R² = 67%), from RR 1.45 when baseline ADR was below 30% to RR 1.08 when it was 45% or higher, and attenuated in more recent and FIT-positive trials. In non-randomised real-world cohorts the pooled effect was smaller and non-significant (odds ratio 1.20 (95% CI 0.98–1.46); very low certainty). Small-study effects were present (Egger P = 0.004), although the trim-and-fill-adjusted estimate remained favourable (RR 1.11). Stand-alone validation series reported per-lesion or per-image sensitivities of approximately 87–100%. Conclusions: CADe-assisted colonoscopy consistently increases the detection of predominantly diminutive, non-advanced adenomas and reduces miss rates, with the greatest gains among lower-performing endoscopists. Its effect on advanced neoplasia, serrated lesions and, ultimately, PCCRC incidence remains unproven, and benefits are attenuated in high-performing and real-world settings. Implementation should be targeted, monitored and coupled with strategies that mitigate automation bias and deskilling.
CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES Muhammad Thoriq Alhabib; Namira Assyfa Nurazizah; Fikri Arif Muhammad; Chaerunnisa Auliya Putu Sugiyarti; Greatavia Meanda Leslie; Srigita Varsha; Dwi Putri Wijayanti; Fitri Nurina Septiana; Bernita Nur Cahyani; Shelda Syifa’ Azzahra; Muhamad Luthfi Asyhar; Charles Sanjaya
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/bhxfav87

Abstract

Background. Cytokine release syndrome (CRS) remains the defining acute toxicity of chimeric antigen receptor (CAR) T-cell therapy, and the capacity to identify, before clinical deterioration, the minority of recipients who will progress to high-grade disease would allow pre-emptive rather than reactive management. Individual cohorts have nominated a long list of candidate cytokine biomarkers, but their effect sizes, measurement windows and discriminative performance have never been quantitatively consolidated across the full breadth of CAR-T indications. Objective. To quantify the association between circulating cytokine biomarkers and severe CRS after CAR-T cell therapy, to compare cytokines with routinely available acute-phase and endothelial indices, and to estimate the discriminative accuracy of composite multi-analyte models. Methods. The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Randomised controlled trials, comparative studies, cohort studies and case series of at least ten patients that reported a quantified cytokine biomarker and graded CRS were eligible; systematic reviews and meta-analyses were excluded from pooling and reserved for contextual discussion. Risk of bias was appraised with ROBINS-I and Cochrane RoB 2. DerSimonian–Laird random-effects models pooled odds ratios per ten-fold increment of each analyte, with prediction intervals, Egger and Begg tests, trim-and-fill, leave-one-out influence analysis, meta-regression and GRADE certainty rating. Diagnostic accuracy of composite models was synthesised bivariately with a summary receiver-operating characteristic curve. Results. Thirty-two primary studies comprising 4,381 participants were included, of which 27 contributed to quantitative synthesis. Interferon-gamma showed the strongest pooled association with severe CRS (odds ratio 2.65 (95% CI 2.13–3.30); I² 34%), followed by interleukin-6 (2.49 (95% CI 2.06–3.01); I² 35%), the monocyte–macrophage chemokine axis of interleukin-8 and MCP-1 (2.24 (95% CI 1.77–2.83)), interleukin-10 (2.15 (95% CI 1.78–2.60)), interleukin-2 and its soluble receptor (1.84 (95% CI 1.45–2.35)) and interleukin-15 (1.70 (95% CI 1.36–2.11)). Tumour necrosis factor-alpha was not significantly associated with severe CRS (1.18 (95% CI 0.96–1.46)). Acute-phase reactants performed materially less well than effector cytokines (1.50 (95% CI 1.30–1.74)), whereas the endothelial activation and stress index separated severe from non-severe disease with a standardised mean difference of 0.49 (95% CI 0.34–0.63). Pre-infusion composite models carried a pooled odds ratio of 2.01 (95% CI 1.70–2.38), significantly weaker than post-infusion sampling (1.60 versus 2.19; P for interaction = 0.002). Composite multi-analyte models achieved a pooled sensitivity of 77.2% (95% CI 70.5–82.7), specificity of 84.4% (79.0–88.6) and a diagnostic odds ratio of 21.0, with a mean reported area under the curve of 0.85. Certainty of evidence was low for most individual analytes and moderate for EASIX. Conclusions. Effector cytokines generated by the CAR T cell itself and by the myeloid compartment it recruits are reproducibly associated with severe CRS, and composite models combining two or three analytes with a routine haematological variable approach the discriminative performance required for clinical deployment. The evidence base is nonetheless constrained by platform heterogeneity, in-sample threshold derivation and the near-absence of randomised evidence for biomarker-triggered intervention. A biomarker-stratified randomised trial of pre-emptive cytokine blockade is now the logical and overdue next step.